|Bid||39.7700 x 800|
|Ask||39.8500 x 900|
|Day's range||39.1700 - 39.9700|
|52-week range||15.2800 - 45.0200|
|PE ratio (TTM)||N/A|
|Earnings date||7 Aug 2018 - 13 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||45.20|
Shares of companies betting on the gene-editing technology known as CRISPR fell sharply on Monday after two studies in the science journal Nature Medicine questioned whether some implementations of the technique might compromise a cell’s anticancer safeguards. Editas Medicine (EDIT) dropped to $35 from $39, and Intellia Therapeutics (NTLA) slid to $24 from $27. With no products yet tested in humans, it’s hard to say whether the market has been over- or undervaluing CRISPR, a chemical tool that has revolutionized scientific research in the past decade with the ability to alter specific parts of the genetic instructions that run every cell.
Editas Medicine (EDIT) is a pharmaceutical company focused on developing therapies based on CRISPR-CAS9 gene editing technology. On June 11, EDIT stock fell ~7.8% to close at $36.15 over concerns that CRISPR CAS-9 Gene Therapy causes cancer.
Shares of gene-therapy companies sank in active trade Monday, after a STAT report that editing a cell’s genome with CRISPR/Cas9 technology might cause cancer. The STAT report said studies by scientists, which were published in Nature Medicine, found cells that had their genomes altered using the CRISPR/Cas9 method had the potential to seed tumors inside a patient. Switzerland-based CRISPR Therapeutics AG’s stock (CRSP) plunged 12.6% with volume ballooning to 8.3 million shares— almost five-times the full-day average of 1.7 million shares.
Medical researchers say two new studies suggest that a cutting-edge therapy to repair defective genes could promote cancer-causing mutations in cells, a possible safety concern that some of the hottest companies in biotechnology may have to account for as they start human trials. The laboratory studies were published Monday in the journal Nature Medicine. Cells with mutations in the gene, called p53, can’t properly stop cells with DNA damage from dividing so the damage can be repaired -- which can be a key driver of cancer.
Shares in biotech stocks Crispr Therapeutics, Editas Medicine and Intellia Therapeutics fell after a scientific publication reported that gene-editing techniques might cause cancer.
Shares of gene editing leaders Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics had an amazing month.
FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.
The phrase "clinical hold" should strike fear in the heart of any biotech investor. Here are a few reasons to make an exception this time.
After the FDA put the company's gene-editing product candidate for sickle cell disease on hold, bargain hunters may want to scoop up some shares. Here's why.
Since the beginning of 2018, Editas Medicine’s (EDIT) share price has risen 5.1% to close at $36.06 on May 23. The stock touched a high of $46 on March 9 and a low of $43.1 on April 30.
Editas Medicine (EDIT) generates revenue from collaborations and research and development. It earned revenue of $3.9 million in Q1 2018 compared to $682,000 in Q1 2017.
Editas Medicine’s (EDIT) core capability in genome editing makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology to create molecules that can specifically edit DNA. Ocular diseases and engineered cell medicines are two areas in which Editas’s research programs have matured. Editas Medicine aims to file an investigational new drug application for this program by mid-2018.
Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals. Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.